| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Preclinical Development | Executive Vice President
1 company
Leslie Holsinger last filed a Form 4 in June 2022, as EVP, Preclinical Development at QNCX. Leslie Holsinger's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 148,080 shares of QNCX. The QNCX filings lean toward selling, a net 40,000 shares.
Leslie Holsinger has 7 Form 4 filings on record from February 2020 to June 2022, all as EVP, Preclinical Development at Quince Therapeutics (QNCX), 2020–2022.
The 15 reported transactions were 6 open-market sales, 5 option or other derivative awards, 2 option exercises and 1 tax withholding, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $1.2M.
The only open-market sale was 40,000 shares of QNCX at an average $30.81 on December 14, 2020, about $1.2M.
Shares as reported in the last Form 4 for each company; the most recent is from June 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 14, 2020 | QNCX Quince Therapeutics, Inc. | Executive Vice President | Sale+OE | 40,000 | $30.81 | $1,232,528.00 | -92.0% |